journal
https://read.qxmd.com/read/37245519/concern-over-cancer-treatment-delays-caused-by-staffing-shortages
#1
JOURNAL ARTICLE
Elizabeth Gourd
No abstract text is available yet for this article.
May 25, 2023: Lancet Oncology
https://read.qxmd.com/read/37211021/new-us-breast-cancer-screening-recommendations
#2
JOURNAL ARTICLE
Priya Venkatesan
No abstract text is available yet for this article.
May 18, 2023: Lancet Oncology
https://read.qxmd.com/read/37211020/estro-2023
#3
JOURNAL ARTICLE
Smriti Patodia
No abstract text is available yet for this article.
May 18, 2023: Lancet Oncology
https://read.qxmd.com/read/37211019/cancer-care-desperately-impeded-by-fighting-in-gaza
#4
JOURNAL ARTICLE
Elizabeth Gourd
No abstract text is available yet for this article.
May 18, 2023: Lancet Oncology
https://read.qxmd.com/read/37207681/g7-cancer-the-priorities-and-challenges-ahead
#5
JOURNAL ARTICLE
Kathryn Senior
No abstract text is available yet for this article.
May 16, 2023: Lancet Oncology
https://read.qxmd.com/read/37187202/radical-cystectomy-versus-trimodality-therapy-for-muscle-invasive-bladder-cancer-a-multi-institutional-propensity-score-matched-and-weighted-analysis
#6
JOURNAL ARTICLE
Alexandre R Zlotta, Leslie K Ballas, Andrzej Niemierko, Katherine Lajkosz, Cynthia Kuk, Gus Miranda, Michael Drumm, Andrea Mari, Ethan Thio, Neil E Fleshner, Girish S Kulkarni, Michael A S Jewett, Robert G Bristow, Charles Catton, Alejandro Berlin, Srikala S Sridhar, Anne Schuckman, Adam S Feldman, Matthew Wszolek, Douglas M Dahl, Richard J Lee, Philip J Saylor, M Dror Michaelson, David T Miyamoto, Anthony Zietman, William Shipley, Peter Chung, Siamak Daneshmand, Jason A Efstathiou
BACKGROUND: Previous randomised controlled trials comparing bladder preservation with radical cystectomy for muscle-invasive bladder cancer closed due to insufficient accrual. Given that no further trials are foreseen, we aimed to use propensity scores to compare trimodality therapy (maximal transurethral resection of bladder tumour followed by concurrent chemoradiation) with radical cystectomy. METHODS: This retrospective analysis included 722 patients with clinical stage T2-T4N0M0 muscle-invasive urothelial carcinoma of the bladder (440 underwent radical cystectomy, 282 received trimodality therapy) who would have been eligible for both approaches, treated at three university centres in the USA and Canada between Jan 1, 2005, and Dec 31, 2017...
May 12, 2023: Lancet Oncology
https://read.qxmd.com/read/37182538/dalpiciclib-plus-letrozole-or-anastrozole-versus-placebo-plus-letrozole-or-anastrozole-as-first-line-treatment-in-patients-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-dawna-2-a-multicentre-randomised-double-blind-placebo-controlled-phase
#7
JOURNAL ARTICLE
Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Wei Li, Quchang Ouyang, Xichun Hu, Ying Cheng, Min Yan, Yueyin Pan, Yuee Teng, Xi Yan, Ying Wang, Weimin Xie, Xiaohua Zeng, Xiaojia Wang, Changlu Hu, Cuizhi Geng, Hongwei Zhang, Wenxin Li, Xinhong Wu, Jincai Zhong, Jingwei Xu, Yanxia Shi, Wenhua Wei, Nayima Bayaxi, Xiaoyu Zhu, Binghe Xu
BACKGROUND: Adding CDK4/6 inhibitor dalpiciclib to fulvestrant significantly prolonged progression-free survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer progressing after endocrine therapy. We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had no previous systemic therapy in the advanced setting. METHODS: DAWNA-2 is a randomised, double-blind, placebo-controlled, phase 3 trial done at 42 hospitals in China...
May 11, 2023: Lancet Oncology
https://read.qxmd.com/read/37182537/long-term-surgical-consequences-of-childhood-cancer
#8
JOURNAL ARTICLE
Danny R Youlden, Jason D Pole, Nancy N Baxter, Joanne F Aitken
No abstract text is available yet for this article.
May 11, 2023: Lancet Oncology
https://read.qxmd.com/read/37182536/cumulative-burden-of-late-major-surgical-intervention-in-survivors-of-childhood-cancer-a-report-from-the-childhood-cancer-survivor-study-ccss-cohort
#9
JOURNAL ARTICLE
Bryan V Dieffenbach, Andrew J Murphy, Qi Liu, Duncan C Ramsey, Erik J Geiger, Lisa R Diller, Rebecca M Howell, Kevin C Oeffinger, Leslie L Robison, Yutaka Yasui, Gregory T Armstrong, Eric J Chow, Brent R Weil, Christopher B Weldon
BACKGROUND: Multimodal cancer therapy places childhood cancer survivors at increased risk for chronic health conditions, subsequent malignancies, and premature mortality as they age. We aimed to estimate the cumulative burden of late (>5 years from cancer diagnosis), major surgical interventions among childhood cancer survivors, compared with their siblings, and to examine associations between specific childhood cancer treatments and the burden of late surgical interventions. METHODS: We analysed data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study with longitudinal prospective follow-up of 5-year survivors of childhood cancer (diagnosed before age 21 years) treated at 31 institutions in the USA, with a comparison group of nearest-age siblings of survivors selected by simple random sampling...
May 11, 2023: Lancet Oncology
https://read.qxmd.com/read/37178709/polygenic-risk-scores-in-cancer-screening-a-glass-half-full-or-half-empty
#10
JOURNAL ARTICLE
Nora Pashayan, Douglas F Easton, Kyriaki Michailidou
No abstract text is available yet for this article.
May 10, 2023: Lancet Oncology
https://read.qxmd.com/read/37178708/utility-of-polygenic-risk-scores-in-uk-cancer-screening-a-modelling-analysis
#11
JOURNAL ARTICLE
Catherine Huntley, Bethany Torr, Amit Sud, Charlie F Rowlands, Rosalind Way, Katie Snape, Helen Hanson, Charles Swanton, John Broggio, Anneke Lucassen, Margaret McCartney, Richard S Houlston, Aroon D Hingorani, Michael E Jones, Clare Turnbull
BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast, prostate, colorectal, pancreas, ovary, kidney, lung, and testicular cancer)...
May 10, 2023: Lancet Oncology
https://read.qxmd.com/read/37156260/south-africa-s-new-tobacco-and-e-cigarette-control-bill
#12
JOURNAL ARTICLE
Manjulika Das
No abstract text is available yet for this article.
May 5, 2023: Lancet Oncology
https://read.qxmd.com/read/37146621/review-of-the-monarche-trial-suggests-no-evidence-to-support-use-of-adjuvant-abemaciclib-in-women-with-breast-cancer
#13
JOURNAL ARTICLE
Tomer Meirson, Daniel A Goldstein, Bishal Gyawali, Ian F Tannock
No abstract text is available yet for this article.
May 2, 2023: Lancet Oncology
https://read.qxmd.com/read/37146620/review-of-the-monarche-trial-suggests-no-evidence-to-support-use-of-adjuvant-abemaciclib-in-women-with-breast-cancer-authors-reply
#14
LETTER
Stephen R D Johnston, Sara M Tolaney, Joyce O'Shaughnessy, Priya Rastogi, Nadia Harbeck, Miguel Martin
No abstract text is available yet for this article.
May 2, 2023: Lancet Oncology
https://read.qxmd.com/read/37088089/eu-cancer-drug-leaflets-contain-insufficient-information
#15
JOURNAL ARTICLE
Elizabeth Gourd
No abstract text is available yet for this article.
April 20, 2023: Lancet Oncology
https://read.qxmd.com/read/37084749/craniopharyngiomas-and-proton-beam-therapy-worth-the-expense
#16
JOURNAL ARTICLE
Ashley Grossman, Michael Kosmin
No abstract text is available yet for this article.
April 18, 2023: Lancet Oncology
https://read.qxmd.com/read/37084748/proton-therapy-and-limited-surgery-for-paediatric-and-adolescent-patients-with-craniopharyngioma-rt2cr-a-single-arm-phase-2-study
#17
JOURNAL ARTICLE
Thomas E Merchant, Mary Ellen Hoehn, Raja B Khan, Noah D Sabin, Paul Klimo, Frederick A Boop, Shengjie Wu, Yimei Li, Elizabeth A Burghen, Niki Jurbergs, Eric S Sandler, Philipp R Aldana, Daniel J Indelicato, Heather M Conklin
BACKGROUND: Compared with photon therapy, proton therapy reduces exposure of normal brain tissue in patients with craniopharyngioma, which might reduce cognitive deficits associated with radiotherapy. Because there are known physical differences between the two methods of radiotherapy, we aimed to estimate progression-free survival and overall survival distributions for paediatric and adolescent patients with craniopharyngioma treated with limited surgery and proton therapy, while monitoring for excessive CNS toxicity...
April 18, 2023: Lancet Oncology
https://read.qxmd.com/read/37080223/adjuvant-chemotherapy-following-chemoradiotherapy-as-primary-treatment-for-locally-advanced-cervical-cancer-versus-chemoradiotherapy-alone-outback-an-international-open-label-randomised-phase-3-trial
#18
JOURNAL ARTICLE
Linda R Mileshkin, Kathleen N Moore, Elizabeth H Barnes, Val Gebski, Kailash Narayan, Madeleine T King, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W Fyles, William Small, David K Gaffney, Pearly Khaw, Susan Brooks, J Spencer Thompson, Warner K Huh, Cara A Mathews, Martin Buck, Aneta Suder, Thomas E Lad, Igor J Barani, Christine H Holschneider, Sylvia Van Dyk, Michael Quinn, Danny Rischin, Bradley J Monk, Martin R Stockler
BACKGROUND: Standard treatment for locally advanced cervical cancer is chemoradiotherapy, but many patients relapse and die of metastatic disease. We aimed to determine the effects on survival of adjuvant chemotherapy after chemoradiotherapy. METHODS: The OUTBACK trial was a multicentre, open-label, randomised, phase 3 trial done in 157 hospitals in Australia, China, Canada, New Zealand, Saudi Arabia, Singapore, and the USA. Eligible participants were aged 18 year or older with histologically confirmed squamous cell carcinoma, adenosquamous cell carcinoma, or adenocarcinoma of the cervix (FIGO 2008 stage IB1 disease with nodal involvement, or stage IB2, II, IIIB, or IVA disease), Eastern Cooperative Oncology Group performance status 0-2, and adequate bone marrow and organ function...
April 17, 2023: Lancet Oncology
https://read.qxmd.com/read/37080222/tislelizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-as-first-line-treatment-for-advanced-or-metastatic-oesophageal-squamous-cell-carcinoma-rationale-306-a-global-randomised-placebo-controlled-phase-3-study
#19
JOURNAL ARTICLE
Jianming Xu, Ken Kato, Eric Raymond, Richard A Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jimenez-Fonseca, Chen-Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H Yoon
BACKGROUND: The options for first-line treatment of advanced oesophageal squamous cell carcinoma are scarce, and the outcomes remain poor. The anti-PD-1 antibody, tislelizumab, has shown antitumour activity in previously treated patients with advanced oesophageal squamous cell carcinoma. We report interim analysis results from the RATIONALE-306 study, which aimed to assess tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma...
April 17, 2023: Lancet Oncology
https://read.qxmd.com/read/37068503/sweeping-new-us-epa-air-pollution-rules
#20
JOURNAL ARTICLE
Bryant Furlow
No abstract text is available yet for this article.
April 14, 2023: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.